Lecanemab-Irmb: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lecanemab-Irmb. Educational only — not medical advice.
Labeled uses
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Source: FDA labeling via NIH DailyMed (set 9d1ff786…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.